
[Music]
I’m gonna talk to you tonight about one
aspect of universities I’ve been doing
this for about 25 years the story is
about transferring results of research
into the marketplace it’s the
continuation of research this field is
called technology transfer and I think
we can do a better job at it what’s the
difference between these mice their size
the sizes due to the production of
growth hormone the larger Mouse produces
more smaller amounts less the mouse in
the middle from this experiment
basically is the control or the natural
stage this work was done in the late
1980s in the laboratories of John Cobb
check and when Chen at Ohio University
what they did is they took the mouse
growth hormone molecule genetically
modified it inserted it into the embryo
and then transplanted the embryo into a
mother host Mouse when the mice were
born they exhibited these
characteristics as they grew up pretty
cool but so what a couple years after
they did this we got involved in
pursuing and applying for a patent and
then in 1992 started a company based
upon this technology with some
entrepreneurs and some people from the
lab the purpose of the company was to
create a drug for hecarim eglee
acromegaly is called human giantism you
may know that from at this time the the
professional wrestler on Andre the Giant
seven foot four and his size was due to
an overproduction
of growth hormone couple years after we
started that company it was purchased by
a pharmaceutical company and that
company pursued clinical trials for the
drug in 2003 it was approved by the Food
and Drug Administration and they started
marketing the drug today it’s a common
part of the medication for acromegaly
that’s technology transfer taking
something from the laboratory moving it
through protecting it and moving it into
a company and into the marketplace I’m
going to talk about another story that
was in a later part of my career your
grandmother comes to visit you she’s not
well she takes a couple of pills for
some diseases that she has while she’s
visiting you she gets sicker you take
her to the doctor the doctor does some
tests comes back and says sorry to say
your grandmother’s developing another
disease but there’s a drug that’s been
recently approved and it really slows
the progression of that disease so the
doctor writes out a script you take it
to the pharmacy the pharmacist fills it
you’re in your car on the way home and
almost sudden there’s a call on your
grandma’s phone picks it up it’s the
pharmacist wait don’t take that drug
call your doctor
what’s going on well the field is called
medication management and about 13 14
years ago Professor Kevin bosun in the
College of Pharmacy at the University
Arizona was studying medication
management in particular looking at drug
interaction going through the literature
and all the data on drug interaction he
and his colleagues developed a software
program we commercialized that
technology by licensing it to a company
that was created in 2013 and a few years
later just not fairly recently that
company was purchased by
a public company at the time of that
purchase the company employed 250 people
and managed drug interaction medication
management for 50 million people that’s
technology transfer moving from the
laboratory and benefiting people so
where do these wicked cool inventions
come from every year the federal
government supports research at
universities to the tune of 30 billion
dollars the research is typically funded
by the research agencies like the
National Institutes of Health the
National Science Foundation and others
faculty apply for that research by
submitting proposals the proposals are
reviewed and about 10 percent of those
proposals are funded and that’s a grant
to the University to do the research and
that’s how researchers is funded at in
most universities so what do we get from
that what do we as taxpayers get from 30
billion dollars for things first and I’m
sure you’ve heard of this the phrase
publish or perish there are 1 million
articles in technical scientific and
medical journals published by faculty
u.s. universities there are reports of
research there reports of the findings
of research this information goes into
the body of knowledge an expanding body
that you and I now can access through
the internet the second are graduates
the people that are doing the work in
the laboratories are typically graduate
students calling them research
assistants when they complete their
masters and doctoral degrees they move
out into the workforce they are the
knowledge workers of our advanced
technology industries in this country a
third is intellectual property there was
a law passed in 1980 at the federal
level
that says that the inventions that are
created from federally funded research
are owned by the University in 2015
there were 25,000 invention reports of
research being done at the University
reported to technology transfer offices
all universities have technology
transfer offices these reports are
basically a sense that someone in the
lab perceives the ability or the
application of something that’s going on
there outside of the lab usually there
are kernel of an idea that has some data
and then what we do is we work to
protect that through patents the fourth
thing is when we license this technology
two types of companies receive
technology from universities companies
that are already in place that are
looking to gain a competitive advantage
by taking that technology in and then
developing it and the development
periods anywheres from five to ten years
and then challenging the incumbent
company in that marketplace the other is
startup companies there were a thousand
startup companies created in 2015 from
lights from technology at universities I
think we can do better than that
so when I think of these inventions my
metaphor is looking out across the
horizon if you’re on the beach you’re
looking across the ocean and you’re
trying to figure out what the hell’s
going on out there is that a oil
platform that an ocean liner well you
can stand there and you can wait and you
can see and maybe they move off maybe
it’s stationary or you can pick up a
pair of binoculars amplify the situation
and scope it out that’s akin to what we
do when these invention
come in to us in a fairly embryonic
state what we do is there’s two elements
that are important in our analysis first
is that technology as evident in the
research patentable can we develop
commercial valid claims from that
technology and kennen issue as a patent
ii we look at the marketplace and I
don’t mean the marketplace today
remember these technologies take after
licensing five to ten years to get to a
point of a product we have to look at
the market in the future what are the
characteristics of that market what are
the needs that market will have when the
needs are identified and we look at our
technology in its characteristics or its
features and there’s congruence we have
an asset we have a commercial asset that
we now need to find a home for in a
company if there’s not congruence well
the science behind that goes into the
body of knowledge this process for us at
the university culminates in a license
agreement a license agreement is a legal
document where one party confers rights
to another party we are granting the
rights for the company to make products
based upon the patents in return the
company obligates itself to develop the
technology and as it moves into
commercialization in their sales we
receive a small percentage of those
sales as royalty universities have
policies that dictate how well these are
divided and they’re fairly consistent
across universities the largest share
typically goes to the inventor or the
inventor group which often includes a
graduate assistant a second chair goes
to support research either
laboratory or broader throughout the
university other shares can go to the
department of the inventor or the
college of the inventor and there is a
share that comes or is retained by the
technology transfer office typically
that’s anywheres from between 15 and up
to 25% therein lies the problem of why
we’re not seeing more technology come
from laboratories into the marketplace
that amount of money is not sufficient
to run a technology transfer office in
large universities universities end up
subsidizing that function let’s think
about this for a second if you have a
technology that is a drug it’s a
blockbuster that produces billions of
dollars of sales and you got a small
percentage of that the royalty that
comes back is pretty significant tens of
millions of dollars you can operate an
office on that kind of a Roth II that’s
a very rare event that’s kind of the way
out on the tail of distribution of what
royalties are all about so if you think
about the resources that come into a
university the expenditures of research
think of it as a PI at some universities
a billion dollars it’s that drawdown of
the thirty billion that I’m talking
about others six hundred million a
couple hundred million etc can you think
of that PI and then you think of the
size of the budget of a technology
transfer office less than 1% so this in
essence is a rate limiter on the
transfer technology coming out of the
laboratory now a few years back
universities were asked why don’t we do
this why don’t we take a percentage of
the research coming in and do a
set-aside put that aside and that money
will be used for technology transfer
research university said no way at a
research university research is
preeminent technology transfer doesn’t
occur by happenstance it’s not a
lightning bolt of an idea it’s years to
get there it’s not luck that is the
reason why we find a company and we
license technology I’m fortunate I work
at a university where the percentage is
greater than 1% work for previously a
president it gets it and the president
now that gets it wants to do more but if
we’re gonna do more across the nation
with all the research universities and
get technology transfer to have more
social impact we got to change the
conversation the conversation today is
about how we can become efficient what
are the best practices the conversation
should be different the conversation
should be what’s necessary to be able to
transfer all that research into the
marketplace and then we’ll talk about
efficiency
I’d assert to you that one percents not
and also say that one percent or any
other percentage that goes into
technology transfer will have a much
greater social impact than if that same
amount of money went to research I just
committed a heresy I’m a heretic at
universities by saying that research is
preeminent but if we’re going to produce
more from research at universities we
have to have that conversation the
conversation is yes it’s important to do
research universities fundamentally
important but research for its own sake
is not sufficient it’s also necessary to
have to do research and transfer that
research for the sake of benefit in the
community that conversation is not going
on at universities thank you
you
[Applause]
I’m gonna talk to you tonight about one
aspect of universities I’ve been doing
this for about 25 years the story is
about transferring results of research
into the marketplace it’s the
continuation of research this field is
called technology transfer and I think
we can do a better job at it what’s the
difference between these mice their size
the sizes due to the production of
growth hormone the larger Mouse produces
more smaller amounts less the mouse in
the middle from this experiment
basically is the control or the natural
stage this work was done in the late
1980s in the laboratories of John Cobb
check and when Chen at Ohio University
what they did is they took the mouse
growth hormone molecule genetically
modified it inserted it into the embryo
and then transplanted the embryo into a
mother host Mouse when the mice were
born they exhibited these
characteristics as they grew up pretty
cool but so what a couple years after
they did this we got involved in
pursuing and applying for a patent and
then in 1992 started a company based
upon this technology with some
entrepreneurs and some people from the
lab the purpose of the company was to
create a drug for hecarim eglee
acromegaly is called human giantism you
may know that from at this time the the
professional wrestler on Andre the Giant
seven foot four and his size was due to
an overproduction
of growth hormone couple years after we
started that company it was purchased by
a pharmaceutical company and that
company pursued clinical trials for the
drug in 2003 it was approved by the Food
and Drug Administration and they started
marketing the drug today it’s a common
part of the medication for acromegaly
that’s technology transfer taking
something from the laboratory moving it
through protecting it and moving it into
a company and into the marketplace I’m
going to talk about another story that
was in a later part of my career your
grandmother comes to visit you she’s not
well she takes a couple of pills for
some diseases that she has while she’s
visiting you she gets sicker you take
her to the doctor the doctor does some
tests comes back and says sorry to say
your grandmother’s developing another
disease but there’s a drug that’s been
recently approved and it really slows
the progression of that disease so the
doctor writes out a script you take it
to the pharmacy the pharmacist fills it
you’re in your car on the way home and
almost sudden there’s a call on your
grandma’s phone picks it up it’s the
pharmacist wait don’t take that drug
call your doctor
what’s going on well the field is called
medication management and about 13 14
years ago Professor Kevin bosun in the
College of Pharmacy at the University
Arizona was studying medication
management in particular looking at drug
interaction going through the literature
and all the data on drug interaction he
and his colleagues developed a software
program we commercialized that
technology by licensing it to a company
that was created in 2013 and a few years
later just not fairly recently that
company was purchased by
a public company at the time of that
purchase the company employed 250 people
and managed drug interaction medication
management for 50 million people that’s
technology transfer moving from the
laboratory and benefiting people so
where do these wicked cool inventions
come from every year the federal
government supports research at
universities to the tune of 30 billion
dollars the research is typically funded
by the research agencies like the
National Institutes of Health the
National Science Foundation and others
faculty apply for that research by
submitting proposals the proposals are
reviewed and about 10 percent of those
proposals are funded and that’s a grant
to the University to do the research and
that’s how researchers is funded at in
most universities so what do we get from
that what do we as taxpayers get from 30
billion dollars for things first and I’m
sure you’ve heard of this the phrase
publish or perish there are 1 million
articles in technical scientific and
medical journals published by faculty
u.s. universities there are reports of
research there reports of the findings
of research this information goes into
the body of knowledge an expanding body
that you and I now can access through
the internet the second are graduates
the people that are doing the work in
the laboratories are typically graduate
students calling them research
assistants when they complete their
masters and doctoral degrees they move
out into the workforce they are the
knowledge workers of our advanced
technology industries in this country a
third is intellectual property there was
a law passed in 1980 at the federal
level
that says that the inventions that are
created from federally funded research
are owned by the University in 2015
there were 25,000 invention reports of
research being done at the University
reported to technology transfer offices
all universities have technology
transfer offices these reports are
basically a sense that someone in the
lab perceives the ability or the
application of something that’s going on
there outside of the lab usually there
are kernel of an idea that has some data
and then what we do is we work to
protect that through patents the fourth
thing is when we license this technology
two types of companies receive
technology from universities companies
that are already in place that are
looking to gain a competitive advantage
by taking that technology in and then
developing it and the development
periods anywheres from five to ten years
and then challenging the incumbent
company in that marketplace the other is
startup companies there were a thousand
startup companies created in 2015 from
lights from technology at universities I
think we can do better than that
so when I think of these inventions my
metaphor is looking out across the
horizon if you’re on the beach you’re
looking across the ocean and you’re
trying to figure out what the hell’s
going on out there is that a oil
platform that an ocean liner well you
can stand there and you can wait and you
can see and maybe they move off maybe
it’s stationary or you can pick up a
pair of binoculars amplify the situation
and scope it out that’s akin to what we
do when these invention
come in to us in a fairly embryonic
state what we do is there’s two elements
that are important in our analysis first
is that technology as evident in the
research patentable can we develop
commercial valid claims from that
technology and kennen issue as a patent
ii we look at the marketplace and I
don’t mean the marketplace today
remember these technologies take after
licensing five to ten years to get to a
point of a product we have to look at
the market in the future what are the
characteristics of that market what are
the needs that market will have when the
needs are identified and we look at our
technology in its characteristics or its
features and there’s congruence we have
an asset we have a commercial asset that
we now need to find a home for in a
company if there’s not congruence well
the science behind that goes into the
body of knowledge this process for us at
the university culminates in a license
agreement a license agreement is a legal
document where one party confers rights
to another party we are granting the
rights for the company to make products
based upon the patents in return the
company obligates itself to develop the
technology and as it moves into
commercialization in their sales we
receive a small percentage of those
sales as royalty universities have
policies that dictate how well these are
divided and they’re fairly consistent
across universities the largest share
typically goes to the inventor or the
inventor group which often includes a
graduate assistant a second chair goes
to support research either
laboratory or broader throughout the
university other shares can go to the
department of the inventor or the
college of the inventor and there is a
share that comes or is retained by the
technology transfer office typically
that’s anywheres from between 15 and up
to 25% therein lies the problem of why
we’re not seeing more technology come
from laboratories into the marketplace
that amount of money is not sufficient
to run a technology transfer office in
large universities universities end up
subsidizing that function let’s think
about this for a second if you have a
technology that is a drug it’s a
blockbuster that produces billions of
dollars of sales and you got a small
percentage of that the royalty that
comes back is pretty significant tens of
millions of dollars you can operate an
office on that kind of a Roth II that’s
a very rare event that’s kind of the way
out on the tail of distribution of what
royalties are all about so if you think
about the resources that come into a
university the expenditures of research
think of it as a PI at some universities
a billion dollars it’s that drawdown of
the thirty billion that I’m talking
about others six hundred million a
couple hundred million etc can you think
of that PI and then you think of the
size of the budget of a technology
transfer office less than 1% so this in
essence is a rate limiter on the
transfer technology coming out of the
laboratory now a few years back
universities were asked why don’t we do
this why don’t we take a percentage of
the research coming in and do a
set-aside put that aside and that money
will be used for technology transfer
research university said no way at a
research university research is
preeminent technology transfer doesn’t
occur by happenstance it’s not a
lightning bolt of an idea it’s years to
get there it’s not luck that is the
reason why we find a company and we
license technology I’m fortunate I work
at a university where the percentage is
greater than 1% work for previously a
president it gets it and the president
now that gets it wants to do more but if
we’re gonna do more across the nation
with all the research universities and
get technology transfer to have more
social impact we got to change the
conversation the conversation today is
about how we can become efficient what
are the best practices the conversation
should be different the conversation
should be what’s necessary to be able to
transfer all that research into the
marketplace and then we’ll talk about
efficiency
I’d assert to you that one percents not
and also say that one percent or any
other percentage that goes into
technology transfer will have a much
greater social impact than if that same
amount of money went to research I just
committed a heresy I’m a heretic at
universities by saying that research is
preeminent but if we’re going to produce
more from research at universities we
have to have that conversation the
conversation is yes it’s important to do
research universities fundamentally
important but research for its own sake
is not sufficient it’s also necessary to
have to do research and transfer that
research for the sake of benefit in the
community that conversation is not going
on at universities thank you
you
[Applause]
Please follow and like us: